Novo Nordisk Weight Loss Drug Shows Promise, But Questions Remain on Safety and Broad Efficacy

• Amycretin, Novo Nordisk's new weight loss drug candidate, showed promising 12% weight reduction in early trial compared to Wegovy's 11.1% in pivotal trials • However, amycretin trial was small (36 Japanese men) and short (12 weeks) so results may not translate to larger populations • Safety and tolerability details were not disclosed, suggesting potential issues • Novo Nordisk doesn't need amycretin to succeed to keep growing - Wegovy just launched in 2021 and sales grew 31% last year • Novo Nordisk stock has already run up 89% in the past year and new expectations are very high, better to wait for more attractive valuation